Testosterone Enanthate Legal and Patent Challenges

FDA Approval History and Early Regulatory Path

Testosterone enanthate received FDA approval in 1954 under the brand name Delatestryl, manufactured by Squibb (later Bristol-Myers Squibb). That makes it one of the longest-marketed injectable androgens in the United States. The original New Drug Application (NDA 009165) was approved under the pre-1962 standards that did not require controlled efficacy trials, and the product was later reviewed under the Drug Efficacy Study Implementation (DESI) program in the 1970s to confirm its therapeutic value met updated scientific criteria [1].

Because the compound patent expired before the Hatch-Waxman Act of 1984 established modern generic drug pathways, testosterone enanthate entered a regulatory gray zone. Multiple manufacturers began producing the drug under Abbreviated New Drug Applications (ANDAs) without the patent litigation that typically accompanies generic entry today. Endo Pharmaceuticals, Pfizer (via its Pharmacia legacy), and several compounding-adjacent manufacturers now sell FDA-approved versions. The absence of patent barriers means that legal challenges around testosterone enanthate center not on intellectual property but on labeling, safety signals, and controlled-substance enforcement [2].

The FDA's Drugs@FDA database lists multiple active ANDAs for testosterone enanthate injection (200 mg/mL), each referencing NDA 009165 as the reference listed drug.

The 2015 Label Revision and Cardiovascular Warnings

In March 2015, the FDA required all testosterone product manufacturers to add new warnings about cardiovascular risk. This was a direct response to two observational studies: a 2013 JAMA retrospective cohort (N=8,709) that reported a 29% increased risk of adverse cardiovascular outcomes in men prescribed testosterone [3], and a 2014 PLOS ONE study (N=55,593) showing elevated myocardial infarction rates in men over 65 within 90 days of filling a testosterone prescription [4].

The label change was significant for three reasons. First, the FDA narrowed the approved indication from "clinical hypogonadism" broadly to hypogonadism caused by specific, documented organic etiologies (genetic disorders, chemotherapy damage, pituitary disease). Second, the agency added a warning about possible increased risk of heart attack and stroke. Third, the label now explicitly stated that safety and efficacy had not been established for age-related hypogonadism, a condition affecting an estimated 2.4 million U.S. men aged 40 to 69 according to the Massachusetts Male Aging Study [5].

This labeling action did not pull the drug from market. It did, however, give plaintiffs' attorneys a regulatory anchor for product liability claims.

Multidistrict Litigation: MDL No. 2545

The Judicial Panel on Multidistrict Litigation consolidated thousands of individual lawsuits against testosterone product manufacturers into MDL No. 2545, assigned to Judge Matthew Kennelly in the Northern District of Illinois in 2014. At peak filing, over 7,000 cases were pending. Plaintiffs alleged that manufacturers promoted testosterone products for age-related low testosterone ("Low T") without adequate warnings about cardiovascular and thromboembolic risks [6].

Several bellwether trials produced mixed results. A jury awarded $150 million in the first bellwether (later reduced), while subsequent cases returned defense verdicts. AbbVie, maker of AndroGel, bore the largest litigation burden, but generic testosterone enanthate manufacturers were named in a subset of cases because the MDL covered all FDA-approved testosterone products regardless of formulation.

Settlement details remain confidential for most defendants. By 2021, the MDL had wound down substantially, with remaining cases remanded to originating courts. The litigation did not result in a market withdrawal or an FDA-mandated recall, but it pressured manufacturers to tighten direct-to-consumer marketing claims and accelerated the FDA's demand for a prospective cardiovascular outcomes trial.

TRAVERSE Trial: The Prospective Answer

The Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial, published in the New England Journal of Medicine in June 2023, enrolled 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease [7]. This was the first large, randomized, placebo-controlled trial specifically designed to assess the cardiovascular safety of testosterone replacement.

The primary endpoint (composite of cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of placebo at a median follow-up of 33 months. The hazard ratio of 0.96 (95% CI, 0.78 to 1.17) met the prespecified non-inferiority margin. Testosterone did not increase MACE risk in this population [7].

TRAVERSE did identify a signal for increased atrial fibrillation (HR 1.29), acute kidney injury (HR 1.28), and pulmonary embolism (HR 1.92, though absolute numbers were small: 15 vs. 9 events). These secondary findings are now under FDA review for potential labeling updates. For testosterone enanthate specifically, these data apply because the trial used 1.62% testosterone gel, and the FDA treats cardiovascular and thromboembolic warnings as class-wide across all testosterone formulations and routes.

The T-Trials, a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older published in the New England Journal of Medicine in 2016, had earlier shown that testosterone treatment increased coronary artery plaque volume (as measured by coronary CT angiography) by a greater amount than placebo [8]. This finding generated concern but was limited by small sample size and a surrogate endpoint. TRAVERSE provided the definitive, adequately powered answer.

DEA Scheduling and Controlled-Substance Enforcement

Testosterone enanthate is a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990, amended by the Anabolic Steroid Control Act of 2004. This classification carries specific legal consequences for prescribers, pharmacies, and patients [9].

Prescriptions require a DEA number. No refills beyond five within six months of the original prescription date. State-level regulations may impose additional restrictions. Telemedicine prescribing of Schedule III substances operated under a COVID-era temporary exemption (the Ryan Haight Act waiver), which Congress extended through the DEA's proposed telemedicine rulemaking. As of early 2026, the DEA has not finalized a permanent telemedicine rule for controlled substances, creating regulatory uncertainty for telehealth TRT providers [10].

Diversion remains an enforcement priority. The DEA reported 228 testosterone-related arrests in fiscal year 2023, many involving underground labs manufacturing raw testosterone enanthate powder imported from overseas and sold without prescriptions. These cases intersect with the broader anabolic steroid black market, estimated at $400 million annually in the U.S. by the Drug Enforcement Administration [11].

For prescribers, the legal risk is real. State medical boards have disciplined physicians for prescribing testosterone without documented lab-confirmed hypogonadism (two morning total testosterone levels <300 ng/dL per the Endocrine Society 2018 guidelines) [12]. The combination of Schedule III status and the narrowed FDA indication creates a compliance framework that penalizes off-guideline prescribing.

REMS Program and Post-Market Surveillance

In 2020, the FDA extended its Risk Evaluation and Mitigation Strategy (REMS) requirements to include testosterone products alongside opioid analgesics in a shared REMS framework addressing abuse and dependence. The testosterone-specific REMS requires a Medication Guide to be distributed with each prescription, educating patients about the risks of misuse, abuse, and dependence [13].

The FDA's Sentinel System conducts ongoing active surveillance for thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke) among testosterone users. Sentinel analyses draw from claims data covering over 100 million patients, providing signal detection that is faster and more representative than the passive MedWatch adverse event reporting system. A 2019 Sentinel analysis found a modest increase in venous thromboembolism risk (OR 1.25, 95% CI 1.05 to 1.49) in the first six months of testosterone use compared to non-users [14].

Post-market requirements (PMRs) issued to testosterone manufacturers include submission of updated literature reviews on cardiovascular and hepatic safety at defined intervals. These PMRs are tracked publicly through the FDA's PMR database and remain open obligations for generic testosterone enanthate ANDA holders.

Compounding Pharmacy Regulation and the 503B Distinction

A substantial volume of testosterone enanthate is produced by compounding pharmacies, operating under either Section 503A (traditional patient-specific compounding) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. The distinction carries major legal implications [15].

503A pharmacies compound pursuant to individual prescriptions and are regulated primarily by state boards of pharmacy. 503B outsourcing facilities may compound without patient-specific prescriptions and sell to healthcare facilities, but must register with the FDA, report adverse events, and comply with current Good Manufacturing Practice (cGMP) requirements.

The FDA has issued multiple warning letters to compounding pharmacies producing testosterone enanthate with potency failures, sterility concerns, or unapproved combinations (such as testosterone enanthate with nandrolone). In 2023, the FDA issued seven warning letters to 503B facilities for testosterone products that failed potency testing, with measured concentrations ranging from 72% to 134% of labeled strength [16]. For patients, this variability means that a prescribed 200 mg dose might deliver anywhere from 144 mg to 268 mg of actual testosterone enanthate, with downstream effects on serum levels, symptom control, and safety.

The legal question of whether compounded testosterone enanthate is a "copy" of a commercially available FDA-approved product (which would make 503B compounding illegal under the FDCA) remains partially unresolved. The FDA has generally enforced against copies but has exercised discretion when drug shortages exist.

State-Level Prescribing Restrictions and Telehealth Variance

Beyond federal regulation, at least 12 states impose additional prescribing requirements for testosterone. Some require in-person physical examinations before initiating controlled-substance prescriptions. Others mandate prescription drug monitoring program (PDMP) checks before each testosterone prescription, treating it identically to opioids for tracking purposes [17].

This patchwork creates compliance complexity for multi-state telehealth platforms prescribing testosterone enanthate. A provider licensed in Florida (which permits Schedule III telehealth prescribing after an audio-video visit) may not apply the same protocol for a patient in Alabama (which requires an in-person exam for initial controlled-substance prescriptions). The legal exposure for getting this wrong includes state medical board sanctions, DEA investigation, and civil liability.

The Alliance for Pharmacy Compounding and the American Telemedicine Association have both filed public comments urging the DEA to establish uniform telehealth prescribing standards for Schedule III hormones, but no final rule has been issued as of this publication date [18].

Ongoing and Anticipated Regulatory Actions

Three regulatory actions are expected to affect testosterone enanthate access and labeling between 2026 and 2028. The FDA's review of TRAVERSE secondary safety signals (atrial fibrillation, pulmonary embolism, acute kidney injury) may trigger another class-wide labeling revision. The DEA's permanent telemedicine prescribing rule, when finalized, will either preserve or restrict current telehealth TRT access for millions of patients. And the FDA's continued enforcement against non-compliant 503B compounding facilities may reduce the supply of lower-cost compounded testosterone enanthate, pushing patients toward branded generics that cost two to four times more per vial [19].

According to the Endocrine Society's 2018 clinical practice guideline, "We recommend against testosterone therapy in men planning fertility in the near term" and specify that treatment should target men with "unequivocally low serum testosterone levels" confirmed by two separate morning measurements [12]. This guideline language has become a de facto medicolegal standard. Providers who document adherence to it are better positioned to defend prescribing decisions against board complaints, malpractice claims, or DEA scrutiny.

Clinicians prescribing testosterone enanthate should maintain documentation of confirmed organic etiology, two morning total testosterone levels <300 ng/dL, shared decision-making regarding cardiovascular risk, and ongoing monitoring including hematocrit checks every 6 to 12 months per the AUA/Endocrine Society consensus [12].